Claims for Patent: 7,727,550

Summary for Patent: 7,727,550

Title:	Biologically active native biomatrix composition
Abstract:	The present disclosure relates to a biologically active biomatrix composition. In one embodiment, the biomatrix composition is derived from human amnions. The biomatrix is termed HuBiogel.TM.. The composition of HuBiogel.TM. closely mimics naturally occurring basement membrane compositions and is capable of supporting a wide variety of cell types in vitro and in vivo. The HuBiogel.TM. biomatrix disclosed comprises, in one embodiment, laminin, collagen I, and collagen IV, and may further comprise any combination of the following: entactin, tenascin, fibronectin and proteoglycans. The biomatrix composition is essentially free of endogenous growth factors and proteolytic enzymes. Also described are two- and three-dimensional culture systems and physiological/pathological model systems utilizing the HuBiogel.TM. compositions. The HuBiogel.TM. compositions may be modified to contain desired growth stimulants, such as growth factors, polypeptides and organic mall molecules, and may also contain growth inhibitory agents and/or therapeutic agents.
Inventor(s):	Siegal; Gene P. (Birmingham, AL), Singh; Raj (Birmingham, AL)
Assignee:	The UAB Research Foundation (Birmingham, AL)
Application Number:	10/546,506
Patent Claims:	1. An isolated biomatrix composition comprising collagen I, collagen IV, laminin, entactin, and tenascin, wherein collagen I is present in a concentration greater than a concentration of collagen IV, laminin, entactin and tenascin, said composition is derived from a human basement membrane tissue and said composition is essentially free of endogenous collagenase. 2. The composition of claim 1 where the two most abundant components are collagen I and collagen IV, each of said collagen I and collagen IV being present in a concentration greater than a concentration of laminin, entactin, or tenascin. 3. The composition of claim 1 where the collagen I is present in a range of 35-46% by weight, collagen IV is present in a range of 19-33% by weight, laminin is present in a range of 16-21% by weight, entactin is present in a range of 7.5 to 14.5% by weight, and tenascin is present in a range of 3.5-7.0% by weight. 4. The composition of claim 1 where the collagen I is present at a concentration of 36% by weight, collagen IV is present at a concentration 24% by weight, laminin is present at a concentration 20% by weight, entactin is present at a concentration of 12.5% by weight, and tenascin is present at a concentration 5% by weight. 5. The composition of claim 1 where said composition is derived from a human placental amnion. 6. The composition of claim 1 where the composition is essentially free of endogenous growth stimulants and proteolytic enzymes. 7. The composition of claim 6 where the growth stimulants are selected from the group consisting of EGF, NGF, FGF, bFGF, VEGF, HGF, BDNF, and GDNF. 8. The composition of claim 1 where said composition is capable of sustaining the viability of a non-transformed target cell type by providing a suitable environment for said non-transformed target cell type without inducing differentiation of said non-transformed target cell type. 9. The composition of claim 8 where the non-transformed target cell type is selected from the group consisting of: epithelial cells, stem cells, endothelial cells, transgenic cells, liver cells and neural cells. 10. The composition of claim 9 where the stem cells are totipotent or pluripotent. 11. The composition of claim 1 where said composition is capable of supporting the controlled growth of transformed cell types. 12. The composition of claim 1 where said composition is used for the study of physiological and pathological processes by culturing a population of target cells relevant to said physiological or pathological processes on the composition of claim 1 and observing at least one characteristic relevant to said physiological process of said target cell culture over time. 13. The composition of claim 12 where the physiological processes are selected from the group consisting of: tissue growth, tissue development, bone remodeling, wound healing, angiogenesis, reproduction, and aging. 14. The composition of claim 12 where the pathological processes are selected from the group consisting of tumorigenesis, metastasis, angiogenesis, vascular dysfunction, arthritis and atherosclerosis. 15. The composition of claim 1 where said composition forms a gel over a temperature range of 4 degrees C. to 37 degrees C.

Details for Patent 7,727,550

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2023-02-21